Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses

Malaria transmission-blocking vaccines (TBVs) aim to elicit human antibodies that inhibit sporogonic development of Plasmodium falciparum in mosquitoes, thereby preventing onward transmission. Pfs48/45 is a leading clinical TBV candidate antigen and is recognized by the most potent transmission-bloc...

Descripción completa

Detalles Bibliográficos
Autores principales: McLeod, Brandon, Mabrouk, Moustafa T., Miura, Kazutoyo, Ravichandran, Rashmi, Kephart, Sally, Hailemariam, Sophia, Pham, Thao P., Semesi, Anthony, Kucharska, Iga, Kundu, Prasun, Huang, Wei-Chiao, Johnson, Max, Blackstone, Alyssa, Pettie, Deleah, Murphy, Michael, Kraft, John C., Leaf, Elizabeth M., Jiao, Yang, van de Vegte-Bolmer, Marga, van Gemert, Geert-Jan, Ramjith, Jordache, King, C. Richter, MacGill, Randall S., Wu, Yimin, Lee, Kelly K., Jore, Matthijs M., King, Neil P., Lovell, Jonathan F., Julien, Jean-Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487866/
https://www.ncbi.nlm.nih.gov/pubmed/35977542
http://dx.doi.org/10.1016/j.immuni.2022.07.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487866/
https://www.ncbi.nlm.nih.gov/pubmed/35977542
http://dx.doi.org/10.1016/j.immuni.2022.07.015

Ejemplares similares